CELLECT BIOTHERAPEUTICS LTD has a total of 32 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2011. It filed its patents most often in EPO (European Patent Office), Australia and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and chemical engineering are CHANGCHUN HUAPU BIOTECHNOLOGY CO LTD, NC MEDICAL RES INC and BIOVEX LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 7 | |
#2 | Australia | 5 | |
#3 | Canada | 4 | |
#4 | United States | 4 | |
#5 | WIPO (World Intellectual Property Organization) | 4 | |
#6 | Republic of Korea | 3 | |
#7 | China | 2 | |
#8 | Israel | 2 | |
#9 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Chemical engineering |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Microorganisms | |
#3 | Therapeutic chemical compounds | |
#4 | Separation | |
#5 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Yarkoni Shai | 29 |
#2 | Almog Tal | 10 |
#3 | Sarel Stern Ina | 6 |
#4 | Askenasy Nadir | 5 |
#5 | Levi-Barzani Hilit | 3 |
#6 | Shai Yarkoni | 1 |
Publication | Filing date | Title |
---|---|---|
CA3110018A1 | Modulation of apoptosis susceptible cells | |
WO2019215737A1 | Methods for expanding adipose-derived stem cells | |
AU2016327285A1 | Methods for propagating mesenchymal stem cells (MSC) for use in transplantation | |
WO2016193986A2 | Selective surfaces for, and methods of, selecting a population of stem and progenitor cells, and uses thereof | |
AU2014333391A1 | Activation of hematopoietic progenitors by pretransplant exposure to death ligands | |
AU2013229008A1 | Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof | |
EP2595637A2 | Regulatory immune cells with enhanced targeted cell death effect |